Skip to main content
. 2016 Mar 29;12(4):e388–e395. doi: 10.1200/JOP.2015.009084

FIG 2.

FIG 2.

(A) Proportion of CCOP and non-CCOP study enrollments that were AYA, by study type and time interval. The proportional enrollment of AYAs in all COG studies and in therapeutic studies, in particular, decreased significantly during the 5-year intervals 2004 through 2008 and 2009 through 2013 (see Methods for calculation of AYA proportional enrollment). (B) Proportion of CCOP therapeutic study enrollments that were AYA, by cancer type and time interval. The proportional enrollment of AYAs in trials classified by cancer type did not change significantly during the study intervals, except for a decrease on ALL studies. (C) Proportion of non-CCOP therapeutic study enrollments that were AYA, by cancer type and time interval. The proportional enrollment of AYAs in trials classified by cancer type did not change significantly during the study intervals, except for an increase in AYA patients with AML and RMS. (D) Proportion of CCOP therapeutic study enrollments versus cancer control study enrollments that were AYA, by time interval. The proportional enrollment of AYAs onto cancer control studies at CCOP sites was significantly lower than in therapeutic studies during both 2004 through 2008 and 2009 through 2013. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AYA, adolescent and young adult; CCOP, Community Clinical Oncology Program; Ewing, Ewing sarcoma; Hodgkin, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; OS, osteosarcoma; RMS, rhabdomyosarcoma.